Persistent nociceptor hyperactivity as a painful evolutionary adaptation is a research paper published in Trends in Neurosciences (2023). On theSindex it has a DataRank of 0. It has been cited 83 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Health and Medical Research Council
Grant: APP1046090
National Health and Medical Research Council
Grant: APP1028887
National Health and Medical Research Council
Grant: APP1026310
Medical Research Council
Grant: MR/W002426/ 1
NIH
Grant: NS111929
NIH
Grant: NS091759
NIH
Grant: NS102161
NIH
Grant: RO1NS111521
National Science Foundation
Grant: IOS 204-7331
NINDS NIH HHS
Grant: R01 NS111521
NINDS NIH HHS
Grant: R01 NS111929
NINDS NIH HHS
Grant: R01 NS091759
NINDS NIH HHS
Grant: R01 NS102161
Cancer Research UK
Grant: 22053
FWCI
17.26
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 26 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 24 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 19 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 23 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 17 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 14 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 13 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 10 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 13 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 9 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 7 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 8 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 4 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 20 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 22 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 19 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 21 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 18 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 17 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling
Additional file 14 of Diversely evolved xibalbin variants from remipede venom inhibit potassium channels and activate PKA-II and Erk1/2 signaling